Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis

Michelle L Apperson, Mark A. Agius

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is an immune-mediated disorder causing inflammation and de-myelination in the central nervous system. As the onset of multiple sclerosis is at a young age, it is one of the leading neurological causes of disability. Disease activity and disability can be measured by neurological assessments and by magnetic resonance imaging. The development of standardized assessments has been a very important step in clinical research in MS. Clinical research in MS has led to a better understanding of the disease itself and has resulted in exciting new therapies. The protocols provided in this unit are four basic clinical and neuroimaging assessments commonly used as outcome measures in clinical research studies of MS subjects. These step-by-step instructions may be used by researchers and neurologists in clinical practice to obtain objective measures of MS disease progression and response to treatments.

Original languageEnglish (US)
Article number10.4
JournalCurrent Protocols in Neuroscience
Issue numberSUPPL.54
DOIs
StatePublished - 2011

Fingerprint

Neuroimaging
Multiple Sclerosis
Research
Pharmaceutical Preparations
Immune System Diseases
Disease Progression
Central Nervous System
Research Personnel
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Inflammation
Therapeutics

Keywords

  • Clinical trials
  • EDSS
  • MRI
  • MSFC
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

@article{0270fee4077b4df19b6977e18a591780,
title = "Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is an immune-mediated disorder causing inflammation and de-myelination in the central nervous system. As the onset of multiple sclerosis is at a young age, it is one of the leading neurological causes of disability. Disease activity and disability can be measured by neurological assessments and by magnetic resonance imaging. The development of standardized assessments has been a very important step in clinical research in MS. Clinical research in MS has led to a better understanding of the disease itself and has resulted in exciting new therapies. The protocols provided in this unit are four basic clinical and neuroimaging assessments commonly used as outcome measures in clinical research studies of MS subjects. These step-by-step instructions may be used by researchers and neurologists in clinical practice to obtain objective measures of MS disease progression and response to treatments.",
keywords = "Clinical trials, EDSS, MRI, MSFC, Multiple sclerosis",
author = "Apperson, {Michelle L} and Agius, {Mark A.}",
year = "2011",
doi = "10.1002/0471142301.ns1004s54",
language = "English (US)",
journal = "Current Protocols in Neuroscience",
issn = "1934-8584",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL.54",

}

TY - JOUR

T1 - Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis

AU - Apperson, Michelle L

AU - Agius, Mark A.

PY - 2011

Y1 - 2011

N2 - Multiple sclerosis (MS) is an immune-mediated disorder causing inflammation and de-myelination in the central nervous system. As the onset of multiple sclerosis is at a young age, it is one of the leading neurological causes of disability. Disease activity and disability can be measured by neurological assessments and by magnetic resonance imaging. The development of standardized assessments has been a very important step in clinical research in MS. Clinical research in MS has led to a better understanding of the disease itself and has resulted in exciting new therapies. The protocols provided in this unit are four basic clinical and neuroimaging assessments commonly used as outcome measures in clinical research studies of MS subjects. These step-by-step instructions may be used by researchers and neurologists in clinical practice to obtain objective measures of MS disease progression and response to treatments.

AB - Multiple sclerosis (MS) is an immune-mediated disorder causing inflammation and de-myelination in the central nervous system. As the onset of multiple sclerosis is at a young age, it is one of the leading neurological causes of disability. Disease activity and disability can be measured by neurological assessments and by magnetic resonance imaging. The development of standardized assessments has been a very important step in clinical research in MS. Clinical research in MS has led to a better understanding of the disease itself and has resulted in exciting new therapies. The protocols provided in this unit are four basic clinical and neuroimaging assessments commonly used as outcome measures in clinical research studies of MS subjects. These step-by-step instructions may be used by researchers and neurologists in clinical practice to obtain objective measures of MS disease progression and response to treatments.

KW - Clinical trials

KW - EDSS

KW - MRI

KW - MSFC

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=79959544026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959544026&partnerID=8YFLogxK

U2 - 10.1002/0471142301.ns1004s54

DO - 10.1002/0471142301.ns1004s54

M3 - Article

C2 - 21207365

AN - SCOPUS:79959544026

JO - Current Protocols in Neuroscience

JF - Current Protocols in Neuroscience

SN - 1934-8584

IS - SUPPL.54

M1 - 10.4

ER -